<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049685</url>
  </required_header>
  <id_info>
    <org_study_id>upeclin/HC/FMB-Unesp-38</org_study_id>
    <nct_id>NCT01049685</nct_id>
  </id_info>
  <brief_title>Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy</brief_title>
  <official_title>Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a &quot;Real Life&quot; Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UPECLIN HC FM Botucatu Unesp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UPECLIN HC FM Botucatu Unesp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective longitudinal cohort study with 36 HIV na誰ve-treatment patients, who started
      therapy with lopinavir/ritonavir or efavirenz (LPV/r or EFZ), follow-up of 36 months. Primary
      endpoint: virological success (HIV RNA &lt;50 copies/mL) in the first six months and at the end
      of the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Either LPV/r or EFZ plus a two nucleoside reverse-transcriptase inhibitors
      (NRTIs) are recommended by the current guidelines all around the world as the main background
      drugs for initial therapy of human immunodeficiency virus type 1 (HIV-1) infection. This
      indication is based in results of clinical trials, but patients who participate in these
      studies usually are greatly motivated to continue their prescribed regimen, and can be
      different from the &quot;real life&quot;. Therefore, clinical practice often cannot reproduce published
      results.

      Methods: A retrospective longitudinal cohort study was performed with 36 na誰ve-treatment
      patients, who started therapy with LPV/r or EFZ, with follow-up of 36 months. The primary
      endpoint was virological success (HIV RNA &lt;50 copies/mL) in the first six months and at the
      end of the study. Effectiveness was examined comparing time to virological failure and CD4
      recovery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance HIV RNA &lt;50 copies/mL at the end oh 36 months</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achieve HIV RNA &lt;50 copies/mL at the first 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Efavirenz Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Na誰ve-treatment HIV patients, who started therapy with Efavirenz</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir/r Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Na誰ve-treatment HIV patients, who started therapy with Lopinavir/ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>First-line Antiretroviral Therapy</intervention_name>
    <description>Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background
Efavirenz: 01 capsules day, plus NRTI background</description>
    <arm_group_label>Efavirenz Group</arm_group_label>
    <arm_group_label>Lopinavir/r Group</arm_group_label>
    <other_name>Sustiva</other_name>
    <other_name>Kaletra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected naive-treatment patients

        Exclusion Criteria:

          -  use of Anti-Retroviral Agents in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre N Barbosa, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Botucatu School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SAE e Hospital Dia Domingos Alves Meira</name>
      <address>
        <city>Botucatu</city>
        <state>SP</state>
        <zip>18603-790</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>February 12, 2010</last_update_submitted>
  <last_update_submitted_qc>February 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Naime Barbosa</name_title>
    <organization>SAE e Hospital Dia Domingos Alves Meira - Faculdade de Medicina de Botucatu - Unesp</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Antiretroviral Therapy, Highly Active</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>Lopinavir</keyword>
  <keyword>Comparative Effectiveness Research</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

